製藥和生物技術分銷貿易：2020-2025

《製藥和生物技術領域的分銷交易》深入理解和分析了公司如何以及為何達成分銷交易。本報告提供了2020年至2025年零售貿易的詳細資訊。

此報告提供雙方宣布的分銷交易的付款條款。這些數據為付款條款和其他貿易條款提供了寶貴的見解。

了解潛在合作夥伴談判交易條款的彈性可以為談判過程提供重要的見解，讓您了解談判條款時會發生什麼。許多中小企業可能會要求詳細的付款條款，但當涉及如何觸發付款和權利轉移時，細節決定成敗。這種見解在新聞稿或資料庫中找不到，而是來自合約文件。

本報告提供了自 2020 年以來宣布的分銷交易的綜合列表，這些交易記錄在“當前協議”交易和合作夥伴關係數據庫中，包括可用的財務條款，以及公司及其合作夥伴向 SEC 提交的實際分銷交易文件的在線副本鏈接。

報告的第一部分涵蓋貿易和商業活動。

第 1 章對報告進行了介紹，第 2 章概述並分析了分銷趨勢，並討論了交易類型的好處。

第 3 章概述了分銷協議的結構。

第 4 章回顧了 2020 年及以後的主要經銷項目。交易按標題價值列出。對於與美國證券交易委員會 (SEC) 公開宣布的協議交易，可以透過目前協議交易和聯盟資料庫中的連結在線存取。

第 5 章提供了最活躍的 25 家經銷商和貿易商的綜合清單。每個交易標題都透過當前協議的交易和聯盟資料庫連結到完整交易記錄的線上版本，並在可用時連結到實際合約文件，從而可以輕鬆按需存取每個交易記錄。

第 6 章對 2020 年以來達成或宣布的分銷交易進行了全面深入的回顧，按公司 A-Z、治療方式、技術和行業垂直分類，並提供合約文件。合約文件詳細介紹了雙方就分銷交易達成的實際條款和條件。

交易目錄包含自 2020 年以來宣布的所有分銷交易的綜合清單。每個清單都按公司 A-Z、治療領域和技術類型組織成交易目錄。每個交易標題透過超連結連結到交易記錄的線上版本，包括實際的合約文件。

該報告還包含大量圖表和圖形，展示了 2020 年及以後的交易趨勢和活動。

目錄

摘要整理

第1章 -簡介

第2章 流通交易趨勢

• 簡介
• 流通交易定義
• 2020年以後的流通交易趨勢
  • 流通交易的各年度轉變，2020年～2025年
  • 各開發階段的流通交易，2020年～2025年
  • 產業各部門的流通交易，2020年～2025年
  • 各治療領域的流通交易，2020年～2025年，
  • 各技術類型的流通交易，2020年～2025年
  • 最活躍的各企業的流通交易，2020年～2025年
  • 純粹的流通交易的屬性
  • 複數零組件交易能放的流通的屬性
• 調整合作夥伴使之有作用流通交易

第3章 流通交易結構概要

• 簡介
• 銷售契約結構
• 更廣泛的聯盟契約的一環的發行權

第4章 -主要流通交易

• 簡介
• 主要的流通交易，各金額

第5章 -最活躍的 25 位經銷商

• 簡介
• 最活躍的流通交易業者主要25公司

包含第6章 -契約名錄的流通交易

• 簡介
• 按契約流通交易，2020年～2025年
• 交易名錄
• 交易名錄- 各企業流通交易一覽(AZ)
• 交易名錄- 各治療領域的流通交易
• 交易名錄- 各技術類型的流通交易
• 關於調查公司
• 目前聯盟
• 目前契約
• Current Partnering的最近的報告標題

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2020 to 2025.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2020
• Browse distribution deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

• Trends in distribution dealmaking in the biopharma industry
• Overview of distribution deal structure
• Directory of distribution deal records covering pharmaceutical and biotechnology
• The leading distribution deals by value
• Most active distribution dealmakers
• The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

• 2.1. Introduction
• 2.2. Definition of distribution deals
• 2.3. Trends in distribution deals since 2020
  • 2.3.1. Distribution dealmaking by year, 2020-2025
  • 2.3.2. Distribution dealmaking by phase of development, 2020-2025
  • 2.3.3. Distribution dealmaking by industry sector, 2020-2025
  • 2.3.4. Distribution dealmaking by therapy area, 2020-2025
  • 2.3.5. Distribution dealmaking by technology type, 2020-2025
  • 2.3.6. Distribution dealmaking by most active company, 2020-2025
  • 2.3.7. Attributes of pure distribution deals
  • 2.3.8. Attributes of distribution in multi-component deals
• 2.4. Aligning partners to make the distribution agreement work

Chapter 3 - Overview of distribution deal structure

• 3.1. Introduction
• 3.2. Distribution agreement structure
• 3.3. Distribution rights as part of a wider alliance agreement

Chapter 4 - Leading distribution deals

• 4.1. Introduction
• 4.2. Top distribution deals by value

Chapter 5 - Top 25 most active distribution dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active distribution dealmakers

Chapter 6 - Distribution deals including contracts directory

• 6.1. Introduction
• 6.2. Distribution deals with contracts 2020-2025
• Deal directory
• Deal directory - distribution dealmaking by companies A-Z
• Deal directory - distribution dealmaking by therapy area
• Deal directory - distribution dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of distribution
• Figure 2: Trends in distribution deal announcements, 2020-2025
• Figure 3: Distribution deals signed at each phase of development, 2020-2025
• Figure 4: Distribution deals by industry sector, 2020-2025
• Figure 5: Distribution deals by therapy area, 2020-2025
• Figure 6: Distribution deals by technology type, 2020-2025
• Figure 7: Top 25 most active distribution dealmakers, 2020-2025
• Figure 8: Issues in implementing distribution agreements
• Figure 9: Distribution agreements - what should a contract include?
• Figure 10: Components of the distribution deal structure
• Figure 11: Top distribution deals by value 2020-2025
• Figure 12: Most active distribution dealmakers 2020-2025